A Single-Dose, Open-Label, Parallel-Group Study to Assess the Pharmacokinetics of Inclisiran in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function (ORION-7)

Trial Profile

A Single-Dose, Open-Label, Parallel-Group Study to Assess the Pharmacokinetics of Inclisiran in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function (ORION-7)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Inclisiran (Primary)
  • Indications Hypercholesterolaemia
  • Focus Pharmacokinetics
  • Acronyms ORION-7
  • Sponsors The Medicines Company
  • Most Recent Events

    • 10 Oct 2017 Planned End Date changed from 1 Aug 2018 to 1 Sep 2018.
    • 10 Oct 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Nov 2017.
    • 10 Oct 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top